Chemotherapy News and Research RSS Feed - Chemotherapy News and Research

Chemotherapy, in its most general sense, is the treatment of disease by chemicals especially by killing micro-organisms or cancerous cells. In popular usage, it refers to antineoplastic drugs used to treat cancer or the combination of these drugs into a cytotoxic standardized treatment regimen.
Study identifies gene that may become resistant to current testicular cancer treatments

Study identifies gene that may become resistant to current testicular cancer treatments

A major research study has uncovered several new genetic mutations that could drive testicular cancer - and also identified a gene which may contribute to tumours becoming resistant to current treatments. [More]
INRS researchers to use new specialized equipment to study environmental equity, male infertility

INRS researchers to use new specialized equipment to study environmental equity, male infertility

With the acquisition of new specialized equipment, INRS researchers Philippe Apparicio, Géraldine Delbès, and Maritza Jaramillo and their teams will be able to advance knowledge and train highly qualified people in the fields of environmental equity, reproductive toxicology, and the treatment of infections. They received a total of over $1 million from the Quebec government and the John R. Evans Leaders Fund of the Canadian Foundation for Innovation. [More]
Eribulin therapy effective in women with metastatic breast cancer

Eribulin therapy effective in women with metastatic breast cancer

An international research team, led by Dartmouth's Peter A. Kaufman, MD, published findings today in the Journal of Clinical Oncology demonstrating that, while not superior to capecitabine, eribulin is an active and well-tolerated therapy in women with metastatic breast cancer (MBC) receiving this therapy as a first, second, or third line chemotherapy regimen. [More]
MU's Kattesh Katti named 2015 Hevesy Medal Award winner for contributing to nanomedicine

MU's Kattesh Katti named 2015 Hevesy Medal Award winner for contributing to nanomedicine

Gold nanoparticles have been proven useful in a number of medical applications. Scientists are developing nanoparticles to produce pharmaceuticals used in the imaging and diagnosis of diseases such as cancer, arthritis, Parkinson's disease and eye degeneration. [More]
ASCO announces cancer Advance of the Year

ASCO announces cancer Advance of the Year

The American Society of Clinical Oncology for the first time announced its cancer Advance of the Year: the transformation of treatment for the most common form of adult leukemia. Until now, many patients with chronic lymphocytic leukemia (CLL) have had few effective treatment options. Four newly approved therapies, however, are poised to dramatically improve the outlook for patients with the disease. [More]
Amrubicin, carboplatin duo efficacious in thymic carcinoma, not invasive thymoma

Amrubicin, carboplatin duo efficacious in thymic carcinoma, not invasive thymoma

Combination therapy with amrubicin and carboplatin is moderately effective in patients with advanced thymic carcinoma, a Japanese study finds, but invasive thymoma patients do not benefit from this regimen. [More]
Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson today announced sales of $18.3 billion for the fourth quarter of 2014, a decrease of 0.6% as compared to the fourth quarter of 2013. Operational results increased 3.9% and the negative impact of currency was 4.5%. Domestic sales increased 7.4%. [More]
FDA removes partial clinical hold on CytRx's aldoxorubicin clinical trials

FDA removes partial clinical hold on CytRx's aldoxorubicin clinical trials

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that the United States Food and Drug Administration has removed the partial clinical hold on the Company's aldoxorubicin clinical trials. [More]
BMG Pharma S.R.L Grants The Exclusive Distribution Rights For Gelx® Oral Gel And Gelx® Spray For The Treatment Of Oral Mucositis In Cancer Patients To FERRER INTERNACIONAL S.A.

BMG Pharma S.R.L Grants The Exclusive Distribution Rights For Gelx® Oral Gel And Gelx® Spray For The Treatment Of Oral Mucositis In Cancer Patients To FERRER INTERNACIONAL S.A.

BMG Pharma S.r.l. today is pleased to announce that it has signed an exclusive distribution agreement with FERRER INTERNACIONAL S.A., granting them the rights to promote, sell and market its own product GelX for the Middle East, Eastern Europe, Russia and North Africa. [More]
Study finds increase in overall survival in patients with metastatic colorectal cancer

Study finds increase in overall survival in patients with metastatic colorectal cancer

With the dawn of the modern era of new chemotherapeutic and biologic agents available for managing their disease, patients with metastatic colorectal cancer are undergoing less surgery for the removal of their primary tumors, according to research from The University of Texas MD Anderson Cancer Center. [More]
3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive licensing deal with PharmAbcine Inc. for the development, manufacturing and marketing of DIG-KT, a bi-specific monoclonal antibody ("mAb") targeting both VEGFR2/KDR and Tie-2 pathways for cancer in the territory of Greater China (including mainland China, Taiwan, Hong Kong and Macau) and Korea. [More]
PharmaMar to begin PM1183 Phase III trial in combination with doxorubicin in SCLC

PharmaMar to begin PM1183 Phase III trial in combination with doxorubicin in SCLC

Zeltia announces today that its pharmaceutical division PharmaMar will start a Phase III trial with PM1183 in combination with doxorubicin against topotecan in SCLC, given the activity observed in an interim analysis of an ongoing Phase Ib trial. The results of this study will be presented at a prominent international cancer meeting this year, which will be soon announced. [More]
Sophia Genetics obtains CE-IVD marking for BRCA1/2 testing solution

Sophia Genetics obtains CE-IVD marking for BRCA1/2 testing solution

Sophia Genetics, the European leader in Data Driven Medicine, has today obtained CE-IVD marking for its solution to detect BRCA1/2 associated genetic variants in live tumours. [More]
High vitamin D levels boost survival for metastatic colorectal cancer patients

High vitamin D levels boost survival for metastatic colorectal cancer patients

According to a new study led by researchers at Dana-Farber Cancer Institute, clinical trial patients with metastatic colorectal cancer who had high levels of vitamin D in their bloodstream prior to treatment with chemotherapy and targeted drugs, survived longer, on average, than patients with lower levels of the vitamin. [More]
Study: Race and ethnicity may affect breast cancer diagnoses, survival

Study: Race and ethnicity may affect breast cancer diagnoses, survival

Among nearly 375,000 U.S. women diagnosed with invasive breast cancer, the likelihood of diagnosis at an early stage, and survival after stage I diagnosis, varied by race and ethnicity, with much of the difference accounted for by biological differences, according to a study in the January 13 issue of JAMA. [More]
Mayo Clinic expert explains difference between severe sepsis and septic shock

Mayo Clinic expert explains difference between severe sepsis and septic shock

Sepsis can be a dangerous complication of almost any type of infection, including influenza, pneumonia and food poisoning; urinary tract infections; bloodstream infections from wounds; and abdominal infections. [More]
Researchers find mechanism that leads to resistance to targeted therapy in melanoma patients

Researchers find mechanism that leads to resistance to targeted therapy in melanoma patients

Moffitt Cancer Center researchers have discovered a mechanism that leads to resistance to targeted therapy in melanoma patients and are investigating strategies to counteract it. Targeted biological therapy can reduce toxicity and improve outcomes for many cancer patients, when compared to the adverse effects of standard chemotherapeutic drugs. [More]
Virginia Tech scientists plan to design virus to switch wound-healing drug into cancer fighter

Virginia Tech scientists plan to design virus to switch wound-healing drug into cancer fighter

At the Virginia Tech Carilion Research Institute, three scientists are planning to create a virus capable of destroying brain cancer. [More]
Two medical organizations recommend use of HPV test for cervical cancer screening

Two medical organizations recommend use of HPV test for cervical cancer screening

Two leading medical organizations say that using a Human papillomavirus (HPV) test alone for cervical cancer screening is an effective alternative to the current recommendation for screening with either cytology (the Pap test) alone or co-testing with cytology and HPV testing. [More]
Mayo Clinic study dispels myth that cancer biopsies cause cancer to spread

Mayo Clinic study dispels myth that cancer biopsies cause cancer to spread

A study of more than 2,000 patients by researchers at Mayo Clinic's campus in Jacksonville, Florida, has dispelled the myth that cancer biopsies cause cancer to spread. In the Jan. 9 online issue of Gut, they show that patients who received a biopsy had a better outcome and longer survival than patients who did not have a biopsy. [More]